Contributions
Abstract: EP1628
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: The introduction of newer therapies for the treatment of multiple sclerosis (MS) is based upon the need to control neurological disability. Halting disability progression is a challenge for therapy since permanent neurological impairment is the most worrisome aspect of MS for patients and their doctors. The objective of this study was to identify whether “older” injectable treatments can lead to MS-related disability control over at least seven years.
Materials and methods: Data were sourced from the MSBase Registry Patients with at least seven years of continuous treatment with any formulation of interferon beta or glatiramer acetate were analyzed. Disability control was defined as no increase in the expanded disability scale score (EDSS) >1-point from baseline. Time to event by index DMT product was analysed via Cox proportional hazards regression.
Results: Of the 546 eligible patients, 379 (69.4%) were female with a mean (SD) age and disease duration at index DMT start of 38.2 years (10.3) and 7.3 years (7.2) respectively. Median (IQR) EDSS at baseline was 2. A total of 225 patients (41.2%) recorded a minimum greater than 1-point increase from their baseline EDSS, sometime during their on-index treatment follow-up. The remaining 321 patients (58.8%) maintained the “disability control” state during follow-up. Median time to event (>1-point increase from baseline) was 12.3 years. There were no significant differences in time to EDSS increase among the different formulations of interferon beta and/or glatiramer acetate.
Conclusion: Patients with MS who respond well to immunomodulatory injectable treatments may exhibit satisfactory control of neurological disability over long-term follow-up.
Disclosure:
Yara Dadalti Fragoso, Tim Spelman, Pierre Duquette, Marc Girard, Maria Trojano, Guillermo Izquierdo, Pierre Grammond, Alessandra Lugaresi, Vincent Van Pesch, Francois Grand´Maison, Celia Oreja-Guevara, Gerardo Iuliano, Roberto Bergamaschi, Maria Edite Rio, Ricardo Fernández Bolaños, Murat Terzi, and Helmut Butzkueven, have no particular conflicts of interest to declare for this abstract. The work was carried out on behalf of MSBase study group, which receives unconditional grants from pharmaceutical industries (Biogen Idec, Novartis, MerckSerono, Genzyme) to support the existence of the database.
Abstract: EP1628
Type: ePoster
Abstract Category: Therapy - disease modifying - 26 Immunomodulation/Immunosuppression
Introduction: The introduction of newer therapies for the treatment of multiple sclerosis (MS) is based upon the need to control neurological disability. Halting disability progression is a challenge for therapy since permanent neurological impairment is the most worrisome aspect of MS for patients and their doctors. The objective of this study was to identify whether “older” injectable treatments can lead to MS-related disability control over at least seven years.
Materials and methods: Data were sourced from the MSBase Registry Patients with at least seven years of continuous treatment with any formulation of interferon beta or glatiramer acetate were analyzed. Disability control was defined as no increase in the expanded disability scale score (EDSS) >1-point from baseline. Time to event by index DMT product was analysed via Cox proportional hazards regression.
Results: Of the 546 eligible patients, 379 (69.4%) were female with a mean (SD) age and disease duration at index DMT start of 38.2 years (10.3) and 7.3 years (7.2) respectively. Median (IQR) EDSS at baseline was 2. A total of 225 patients (41.2%) recorded a minimum greater than 1-point increase from their baseline EDSS, sometime during their on-index treatment follow-up. The remaining 321 patients (58.8%) maintained the “disability control” state during follow-up. Median time to event (>1-point increase from baseline) was 12.3 years. There were no significant differences in time to EDSS increase among the different formulations of interferon beta and/or glatiramer acetate.
Conclusion: Patients with MS who respond well to immunomodulatory injectable treatments may exhibit satisfactory control of neurological disability over long-term follow-up.
Disclosure:
Yara Dadalti Fragoso, Tim Spelman, Pierre Duquette, Marc Girard, Maria Trojano, Guillermo Izquierdo, Pierre Grammond, Alessandra Lugaresi, Vincent Van Pesch, Francois Grand´Maison, Celia Oreja-Guevara, Gerardo Iuliano, Roberto Bergamaschi, Maria Edite Rio, Ricardo Fernández Bolaños, Murat Terzi, and Helmut Butzkueven, have no particular conflicts of interest to declare for this abstract. The work was carried out on behalf of MSBase study group, which receives unconditional grants from pharmaceutical industries (Biogen Idec, Novartis, MerckSerono, Genzyme) to support the existence of the database.